
Zeger Debyser

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4302308/publications.pdf Version: 2024-02-01



7FCED DERVSED

#	Article	IF	CITATIONS
1	LEDGF/p75-mediated chemoresistance of mixed-lineage leukemia involves cell survival pathways and super enhancer activators. Cancer Gene Therapy, 2022, 29, 133-140.	4.6	7
2	Design, synthesis, in silico studies, and antiproliferative evaluations of novel indolin-2-one derivatives containing 3-hydroxy-4-pyridinone fragment. Bioorganic and Medicinal Chemistry Letters, 2022, 70, 128784.	2.2	3
3	Expansion microscopy allows high resolution single cell analysis of epigenetic readers. Nucleic Acids Research, 2022, 50, e100-e100.	14.5	4
4	Single-Cell Imaging Shows That the Transcriptional State of the HIV-1 Provirus and Its Reactivation Potential Depend on the Integration Site. MBio, 2022, 13, .	4.1	11
5	LEDGINs, Inhibitors of the Interaction Between HIV-1 Integrase and LEDGF/p75, Are Potent Antivirals with a Potential to Cure HIV Infection. Advances in Experimental Medicine and Biology, 2021, 1322, 97-114.	1.6	6
6	Towards a Functional Cure of HIV-1: Insight Into the Chromatin Landscape of the Provirus. Frontiers in Microbiology, 2021, 12, 636642.	3.5	9
7	GS-9822, a Preclinical LEDGIN Candidate, Displays a Block-and-Lock Phenotype in Cell Culture. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	17
8	Role of Transportin-SR2 in HIV-1 Nuclear Import. Viruses, 2021, 13, 829.	3.3	6
9	Unlike its Paralog LEDGF/p75, HRP-2 Is Dispensable for MLL-R Leukemogenesis but Important for Leukemic Cell Survival. Cells, 2021, 10, 192.	4.1	5
10	CRISPR/Cas9-Induced Mutagenesis Corroborates the Role of Transportin-SR2 in HIV-1 Nuclear Import. Microbiology Spectrum, 2021, 9, e0133621.	3.0	3
11	A ubiquitous disordered protein interaction module orchestrates transcription elongation. Science, 2021, 374, 1113-1121.	12.6	34
12	Molecular Mechanism of LEDGF/p75 Dimerization. Structure, 2020, 28, 1288-1299.e7.	3.3	4
13	Imaging the Replication of Single Viruses: Lessons Learned from HIV and Future Challenges To Overcome. ACS Nano, 2020, 14, 10775-10783.	14.6	4
14	Phenotyping of Rare CFTR Mutations Reveals Distinct Trafficking and Functional Defects. Cells, 2020, 9, 754.	4.1	23
15	The chromatin landscape at the HIV-1 provirus integration site determines viral expression. Nucleic Acids Research, 2020, 48, 7801-7817.	14.5	42
16	Block-And-Lock Strategies to Cure HIV Infection. Viruses, 2020, 12, 84.	3.3	109
17	Capsid-Labelled HIV To Investigate the Role of Capsid during Nuclear Import and Integration. Journal of Virology, 2020, 94, .	3.4	34
18	Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using in silico Structure-Based Combinatorial Library Design Approach. Frontiers in Chemistry, 2019, 7, 574.	3.6	32

#	Article	IF	CITATIONS
19	Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing. Nature Communications, 2019, 10, 3556.	12.8	61
20	The mutation of Transportin 3 gene that causes limb girdle muscular dystrophy 1F induces protection against HIV-1 infection. PLoS Pathogens, 2019, 15, e1007958.	4.7	22
21	Design of reverse transcriptase–specific nucleosides to visualize early steps of HIV-1 replication by click labeling. Journal of Biological Chemistry, 2019, 294, 11863-11875.	3.4	5
22	Impact of LEDGIN treatment during virus production on residual HIV-1 transcription. Retrovirology, 2019, 16, 8.	2.0	22
23	Propargylated Purine Deoxynucleosides: New Tools for Fluorescence Imaging Strategies. Molecules, 2019, 24, 468.	3.8	6
24	Targeted editing of the PSIP1 gene encoding LEDGF/p75 protects cells against HIV infection. Scientific Reports, 2019, 9, 2389.	3.3	10
25	Establishment of latent HIV-1 reservoirs: what do we really know?. Journal of Virus Eradication, 2019, 5, 3-9.	0.5	69
26	The free energy landscape of retroviral integration. Nature Communications, 2019, 10, 4738.	12.8	17
27	Post-mitotic BET-induced reshaping of integrase quaternary structure supports wild-type MLV integration. Nucleic Acids Research, 2019, 47, 1195-1210.	14.5	18
28	Insight in HIV Integration Site Selection Provides a Block-and-Lock Strategy for a Functional Cure of HIV Infection. Viruses, 2019, 11, 12.	3.3	26
29	Synthesis, Molecular Modelling and Biological Studies of 3-hydroxypyrane- 4-one and 3-hydroxy-pyridine-4-one Derivatives as HIV-1 Integrase Inhibitors. Medicinal Chemistry, 2019, 15, 755-770.	1.5	22
30	Establishment of latent HIV-1 reservoirs: what do we really know?. Journal of Virus Eradication, 2019, 5, 3-9.	0.5	38
31	LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis. Blood, 2018, 131, blood-2017-05-786962.	1.4	32
32	Inhibitors of the integrase–transportin-SR2 interaction block HIV nuclear import. Retrovirology, 2018, 15, 5.	2.0	14
33	Analysis of ex vivo HIV-1 infection in a controller-discordant couple. Journal of Virus Eradication, 2018, 4, 170-173.	0.5	3
34	Affinity switching of the LEDGF/p75 IBD interactome is governed by kinase-dependent phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7053-E7062.	7.1	27
35	Y-box-binding protein 1 supports the early and late steps of HIV replication. PLoS ONE, 2018, 13, e0200080.	2.5	11

Role of LEDGF/p75 in Cell Biology and Disease Pathogenesis. , 2018, , 1830-1844.

#	Article	IF	CITATIONS
37	Identification and Validation of HIV Cofactors. , 2018, , 1043-1047.		Ο
38	Cellular Cofactors of HIV as Drug Targets. , 2018, , 253-259.		0
39	Role of Transportin-SR2 (Transportin-3, TRN-SR2, TNPO3) in HIV Replication. , 2018, , 1851-1856.		Ο
40	Analysis of HIV-1 infection in a controller-discordant couple. Journal of Virus Eradication, 2018, 4, 170-173.	0.5	2
41	Engineering Next-Generation BET-Independent MLV Vectors for Safer Gene Therapy. Molecular Therapy - Nucleic Acids, 2017, 7, 231-245.	5.1	19
42	N-terminal half of transportin SR2 interacts with HIV integrase. Journal of Biological Chemistry, 2017, 292, 9699-9710.	3.4	11
43	Dual role of the chromatin-binding factor PHF13 in the pre- and post-integration phases of HIV-1 replication. Open Biology, 2017, 7, 170115.	3.6	10
44	Protein–protein and protein–chromatin interactions of LEDGF/p75 as novel drug targets. Drug Discovery Today: Technologies, 2017, 24, 25-31.	4.0	21
45	Insight into HIV-2 latency may disclose strategies for a cure for HIV-1 infection. Journal of Virus Eradication, 2017, 3, 7-14.	0.5	13
46	Insight into HIV-2 latency may disclose strategies for a cure for HIV-1 infection. Journal of Virus Eradication, 2017, 3, 7-14.	0.5	3
47	Towards a Safer, More Randomized Lentiviral Vector Integration Profile Exploring Artificial LEDGF Chimeras. PLoS ONE, 2016, 11, e0164167.	2.5	24
48	A novel translational model for fetoscopic intratracheal delivery of nanoparticles in piglets. Prenatal Diagnosis, 2016, 36, 926-934.	2.3	6
49	LEDGIN-mediated Inhibition of Integrase–LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIV. EBioMedicine, 2016, 8, 248-264.	6.1	90
50	Rational Design, Synthesis and Evaluation of Coumarin Derivatives as Proteinâ€protein Interaction Inhibitors. Molecular Informatics, 2016, 35, 460-473.	2.5	6
51	An integrated multi-electrode-optrode array for in vitro optogenetics. Scientific Reports, 2016, 6, 20353.	3.3	36
52	Dynamic Oligomerization of Integrase Orchestrates HIV Nuclear Entry. Scientific Reports, 2016, 6, 36485.	3.3	28
53	Preclinical Evaluation of a P2X7 Receptor–Selective Radiotracer: PET Studies in a Rat Model with Local Overexpression of the Human P2X7 Receptor and in Nonhuman Primates. Journal of Nuclear Medicine, 2016, 57, 1436-1441.	5.0	77
54	2-hydroxyisoquinoline-1,3(2 H ,4 H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4. European Journal of Medicinal Chemistry, 2016, 117, 256-268.	5.5	11

#	Article	IF	CITATIONS
55	Lessons Learned: HIV Points the Way Towards Precision Treatment of Mixed-Lineage Leukemia. Trends in Pharmacological Sciences, 2016, 37, 660-671.	8.7	8
56	Noninvasive Imaging Reveals Stable Transgene Expression in Mouse Airways After Delivery of a Nonintegrating Recombinant Adeno-Associated Viral Vector. Human Gene Therapy, 2016, 27, 60-71.	2.7	10
57	Comparative Analysis of HIV-1 and Murine Leukemia Virus Three-Dimensional Nuclear Distributions. Journal of Virology, 2016, 90, 5205-5209.	3.4	17
58	High-content analysis of α-synuclein aggregation and cell death in a cellular model of Parkinson's disease. Journal of Neuroscience Methods, 2016, 261, 117-127.	2.5	13
59	rAAV-CFTRΔR Rescues the Cystic Fibrosis Phenotype in Human Intestinal Organoids and Cystic Fibrosis Mice. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 288-298.	5.6	55
60	Retroviral integration: Site matters. BioEssays, 2015, 37, 1202-1214.	2.5	61
61	Kuwanonâ€L as a New Allosteric HIVâ€L Integrase Inhibitor: Molecular Modeling and Biological Evaluation. ChemBioChem, 2015, 16, 2507-2512.	2.6	39
62	HIV-1 integrase inhibition: looking at cofactor interactions. Future Medicinal Chemistry, 2015, 7, 2407-2410.	2.3	9
63	Evaluation of the expression pattern of rAAV2/1, 2/5, 2/7, 2/8, and 2/9 serotypes with different promoters in the mouse visual cortex. Journal of Comparative Neurology, 2015, 523, 2019-2042.	1.6	44
64	HIV-1 IN/Pol recruits LEDGF/p75 into viral particles. Retrovirology, 2015, 12, 16.	2.0	19
65	Serotype-dependent transduction efficiencies of recombinant adeno-associated viral vectors in monkey neocortex. Neurophotonics, 2015, 2, 031209.	3.3	43
66	Host factors for retroviral integration site selection. Trends in Biochemical Sciences, 2015, 40, 108-116.	7.5	83
67	FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an α-synuclein-based rat model for Parkinson's disease. Neurobiology of Aging, 2015, 36, 1559-1568.	3.1	68
68	Multiple cellular proteins interact with LEDGF/p75 through a conserved unstructured consensus motif. Nature Communications, 2015, 6, 7968.	12.8	53
69	Discovery of N-aryl-naphthylamines as inÂvitro inhibitors of the interaction between HIV integrase and the cofactor LEDGF/p75. European Journal of Medicinal Chemistry, 2015, 101, 288-294.	5.5	16
70	Optimization of rhodanine scaffold for the development of protein–protein interaction inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 3208-3214.	3.0	4
71	Five-drug antiretroviral therapy for primary HIV infection?. Lancet Infectious Diseases, The, 2015, 15, 362-363.	9.1	0
72	Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors. Neurobiology of Aging, 2015, 36, 1543-1558.	3.1	75

#	Article	IF	CITATIONS
73	PET imaging of TSPO in a rat model of local neuroinflammation induced by intracerebral injection of lipopolysaccharide. Nuclear Medicine and Biology, 2015, 42, 753-761.	0.6	48
74	Evaluation of the expression pattern of rAAV2/1, 2/5, 2/7, 2/8, and 2/9 serotypes with different promoters in the mouse visual cortex. Journal of Comparative Neurology, 2015, 523, Spc1-Spc1.	1.6	1
75	Targeting Virus-host Interactions of HIV Replication. Current Topics in Medicinal Chemistry, 2015, 16, 1167-1190.	2.1	14
76	Optimization of Multimodal Imaging of Mesenchymal Stem Cells Using the Human Sodium Iodide Symporter for PET and Cerenkov Luminescence Imaging. PLoS ONE, 2014, 9, e94833.	2.5	32
77	The HIV-1 Integrase Mutant R263A/K264A Is 2-fold Defective for TRN-SR2 Binding and Viral Nuclear Import. Journal of Biological Chemistry, 2014, 289, 25351-25361.	3.4	28
78	Noninvasive Bioluminescence Imaging of α-Synuclein Oligomerization in Mouse Brain Using Split Firefly Luciferase Reporters. Journal of Neuroscience, 2014, 34, 16518-16532.	3.6	24
79	LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 – 2014). Expert Opinion on Therapeutic Patents, 2014, 24, 609-632.	5.0	61
80	Structure of transportin SR2, a karyopherin involved in human disease, in complex with Ran. Acta Crystallographica Section F, Structural Biology Communications, 2014, 70, 723-729.	0.8	11
81	Diketoacid chelating ligands as dual inhibitors of HIV-1 integration process. European Journal of Medicinal Chemistry, 2014, 78, 425-430.	5.5	17
82	Viral vectors expressing a single microRNA-based short-hairpin RNA result in potent gene silencing in vitro and in vivo. Journal of Biotechnology, 2014, 169, 71-81.	3.8	22
83	Immunological Ignorance Allows Long-Term Gene Expression After Perinatal Recombinant Adeno-Associated Virus-Mediated Gene Transfer to Murine Airways. Human Gene Therapy, 2014, 25, 517-528.	2.7	16
84	HIV-1 Integrase Variants Retarget Viral Integration and Are Associated with Disease Progression in a Chronic Infection Cohort. Cell Host and Microbe, 2014, 16, 651-662.	11.0	44
85	BET-independent MLV-based Vectors Target Away From Promoters and Regulatory Elements. Molecular Therapy - Nucleic Acids, 2014, 3, e179.	5.1	43
86	Structure, mechanics, and binding mode heterogeneity of LEDGF/p75–DNA nucleoprotein complexes revealed by scanning force microscopy. Nanoscale, 2014, 6, 4611-4619.	5.6	24
87	Validation of host factors of HIV integration as novel drug targets for anti-HIV therapy. MedChemComm, 2014, 5, 314-320.	3.4	4
88	Investigation of a Novel Series of 2-Hydroxyisoquinoline-1,3(2 <i>H</i> ,4 <i>H</i>)-diones as Human Immunodeficiency Virus Type 1 Integrase Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 4640-4660.	6.4	24
89	Design and discovery of 5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxamide inhibitors of HIV-1 integrase. Bioorganic and Medicinal Chemistry, 2014, 22, 5446-5453.	3.0	15
90	Synthesis and biological evaluation of novel antiviral agents as protein–protein interaction inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, 29, 237-242.	5.2	8

#	Article	IF	CITATIONS
91	HIV Virions as Nanoscopic Test Tubes for Probing Oligomerization of the Integrase Enzyme. ACS Nano, 2014, 8, 3531-3545.	14.6	11
92	Switching STRATEGIES in HIV treatment. Lancet Infectious Diseases, The, 2014, 14, 537-540.	9.1	4
93	Bioluminescence imaging of stroke-induced endogenous neural stem cell response. Neurobiology of Disease, 2014, 69, 144-155.	4.4	27
94	A new potential approach to block HIV-1 replication via protein–protein interaction and strand-transfer inhibition. Bioorganic and Medicinal Chemistry, 2014, 22, 2269-2279.	3.0	17
95	Fragment hopping approach directed at design of HIV IN-LEDGF/p75 interaction inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 1002-1009.	5.2	12
96	LEDCINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions. Retrovirology, 2013, 10, 57.	2.0	127
97	New scaffolds of natural origin as Integrase–LEDGF/p75 interaction inhibitors: Virtual screening and activity assays. European Journal of Medicinal Chemistry, 2013, 68, 405-411.	5.5	13
98	Discovery of a novel 5-carbonyl-1H-imidazole-4-carboxamide class of inhibitors of the HIV-1 integrase–LEDGF/p75 interaction. Bioorganic and Medicinal Chemistry, 2013, 21, 5963-5972.	3.0	48
99	The remarkable conformational plasticity of alpha-synuclein: blessing or curse?. Trends in Molecular Medicine, 2013, 19, 368-377.	6.7	79
100	Bromodomain and extra-terminal (BET) proteins target Moloney murine leukemia virus integration to transcription start sites. Retrovirology, 2013, 10, .	2.0	0
101	LEDGF/p75 controls 3D-localization of HIV-1 provirus in the nuclear compartment of infected cells. Retrovirology, 2013, 10, .	2.0	0
102	2-Hydroxyisoquinoline-1,3(2H, 4H)diones (HQDs), novel inhibitors of the HIV integrase catalytic activity with a high barrier to resistance. Retrovirology, 2013, 10, .	2.0	0
103	Identification of small peptides inhibiting the integrase‣EDGF/p75 interaction through targeting the cellular coâ€factor. Journal of Peptide Science, 2013, 19, 651-658.	1.4	9
104	HIV-1 Integrase Drug Discovery Comes of Age. Topics in Medicinal Chemistry, 2013, , 1-52.	0.8	4
105	The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy. Virology, 2013, 435, 102-109.	2.4	96
106	Longâ€ŧerm reversal of diabetes in nonâ€obese diabetic mice by liverâ€directed gene therapy. Journal of Gene Medicine, 2013, 15, 28-41.	2.8	30
107	Discovery of novel inhibitors of LEDGF/p75-IN protein–protein interactions. Bioorganic and Medicinal Chemistry, 2013, 21, 957-963.	3.0	23
108	Rational design of LEDGINs as first allosteric integrase inhibitors for the treatment of HIV infection. Drug Discovery Today: Technologies, 2013, 10, e517-e522.	4.0	7

#	Article	IF	CITATIONS
109	2-Hydroxyisoquinoline-1,3(2 <i>H</i> ,4 <i>H</i>)-diones (HIDs), Novel Inhibitors of HIV Integrase with a High Barrier to Resistance. ACS Chemical Biology, 2013, 8, 1187-1194.	3.4	25
110	The BET Family of Proteins Targets Moloney Murine Leukemia Virus Integration near Transcription Start Sites. Cell Reports, 2013, 5, 886-894.	6.4	162
111	Fragment-Based Discovery of 8-Hydroxyquinoline Inhibitors of the HIV-1 Integrase–Lens Epithelium-Derived Growth Factor/p75 (IN–LEDGF/p75) Interaction. Journal of Medicinal Chemistry, 2013, 56, 2311-2322.	6.4	55
112	The α Crystallin Domain of Small Heat Shock Protein b8 (Hspb8) Acts as Survival and Differentiation Factor in Adult Hippocampal Neurogenesis. Journal of Neuroscience, 2013, 33, 5785-5796.	3.6	27
113	4-Substituted 2-Hydroxyisoquinoline-1,3(2 <i>H</i> ,4 <i>H</i>)-diones as a Novel Class of HIV-1 Integrase Inhibitors. ACS Medicinal Chemistry Letters, 2013, 4, 606-611.	2.8	52
114	Design of Cell-Permeable Stapled Peptides as HIV-1 Integrase Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 5601-5612.	6.4	44
115	Characterization of rare lens epithelium-derived growth factor/p75 genetic variants identified in HIV-1 long-term nonprogressors. Aids, 2013, 27, 539-543.	2.2	7
116	Single-Cell Imaging of HIV-1 Provirus (SCIP). Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5636-5641.	7.1	56
117	Interaction of Transportin-SR2 with Ras-related Nuclear Protein (Ran) GTPase. Journal of Biological Chemistry, 2013, 288, 25603-25613.	3.4	10
118	Cellular Cofactors of HIV as Drug Targets. , 2013, , 1-7.		0
119	Role of Transportin-SR2 (Transportin-3, TRN-SR2, TNPO3) in HIV Replication. , 2013, , 1-5.		0
120	Transient Expression of an LEDGF/p75 Chimera Retargets Lentivector Integration and Functionally Rescues in a Model for X-CGD. Molecular Therapy - Nucleic Acids, 2013, 2, e77.	5.1	13
121	Role of LEDGF/p75 in Cell Biology and Disease Pathogenesis. , 2013, , 1-16.		0
122	Identification and Validation of HIV Cofactors. , 2013, , 1-6.		0
123	LEDGF/p75-Independent HIV-1 Replication Demonstrates a Role for HRP-2 and Remains Sensitive to Inhibition by LEDGINs. PLoS Pathogens, 2012, 8, e1002558.	4.7	117
124	Galectin-1 in Melanoma Biology and Related Neo-Angiogenesis Processes. Journal of Investigative Dermatology, 2012, 132, 2245-2254.	0.7	64
125	The Stress Oncoprotein LEDGF/p75 Interacts with the Methyl CpG Binding Protein MeCP2 and Influences Its Transcriptional Activity. Molecular Cancer Research, 2012, 10, 378-391.	3.4	39
126	Lens Epithelium-derived Growth Factor/p75 Qualifies as a Target for HIV Gene Therapy in the NSG Mouse Model. Molecular Therapy, 2012, 20, 908-917.	8.2	16

#	Article	IF	CITATIONS
127	Regulator of Gâ€protein signaling 18 controls megakaryopoiesis and the ciliaâ€mediated vertebrate mechanosensory system. FASEB Journal, 2012, 26, 2125-2136.	0.5	29
128	Interaction of the HIV-1 Intasome with Transportin 3 Protein (TNPO3 or TRN-SR2). Journal of Biological Chemistry, 2012, 287, 34044-34058.	3.4	52
129	Cellular Cofactors of Lentiviral Integrase: From Target Validation to Drug Discovery. Molecular Biology International, 2012, 2012, 1-16.	1.7	26
130	A Novel Surgical Approach for Intratracheal Administration of Bioactive Agents in a Fetal Mouse Model. Journal of Visualized Experiments, 2012, , .	0.3	7
131	Quad's in it for antiretroviral therapy?. Lancet, The, 2012, 379, 2403-2405.	13.7	8
132	Design of a Novel Cyclotide-Based CXCR4 Antagonist with Anti-Human Immunodeficiency Virus (HIV)-1 Activity. Journal of Medicinal Chemistry, 2012, 55, 10729-10734.	6.4	117
133	Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF. Expert Opinion on Pharmacotherapy, 2012, 13, 1969-1983.	1.8	9
134	Quantitative evaluation of MRI-based tracking of ferritin-labeled endogenous neural stem cell progeny in rodent brain. NeuroImage, 2012, 62, 367-380.	4.2	59
135	Small-Molecule Inhibitors of the LEDGF/p75 Binding Site of Integrase Block HIV Replication and Modulate Integrase Multimerization. Antimicrobial Agents and Chemotherapy, 2012, 56, 4365-4374.	3.2	158
136	Elvitegravir: a once daily alternative to raltegravir. Lancet Infectious Diseases, The, 2012, 12, 3-5.	9.1	10
137	Nitrogen-containing polyhydroxylated aromatics as HIV-1 integrase inhibitors: synthesis, structure-activity relationship analysis, and biological activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2012, 27, 628-640.	5.2	3
138	Preclinical evaluation of [11C]NE40, a type 2 cannabinoid receptor PET tracer. Nuclear Medicine and Biology, 2012, 39, 389-399.	0.6	61
139	Identification of Residues in the C-terminal Domain of HIV-1 Integrase That Mediate Binding to the Transportin-SR2 Protein. Journal of Biological Chemistry, 2012, 287, 34059-34068.	3.4	26
140	HRP-2 determines HIV-1 integration site selection in LEDGF/p75 depleted cells. Retrovirology, 2012, 9, 84.	2.0	57
141	Fueling HIV-1 integrase drug design with structural insights. Drug Discovery Today: Technologies, 2012, 9, e205-e212.	4.0	6
142	Preliminary validation of varicella zoster virus thymidine kinase as a novel reporter gene for PET. Nuclear Medicine and Biology, 2012, 39, 1266-1274.	0.6	10
143	De novo design of small molecule inhibitors targeting the LEDGF/p75-HIVintegrase interaction. RSC Advances, 2012, 2, 974-984.	3.6	13
144	Pathway specific gene expression profiling reveals oxidative stress genes potentially regulated by transcription coâ€activator LEDGF/p75 in prostate cancer cells. Prostate, 2012, 72, 597-611.	2.3	22

#	Article	IF	CITATIONS
145	Phage Display-directed Discovery of LEDGF/p75 Binding Cyclic Peptide Inhibitors of HIV Replication. Molecular Therapy, 2012, 20, 2064-2075.	8.2	49
146	Development of an AlphaScreen-Based HIV-1 Integrase Dimerization Assay for Discovery of Novel Allosteric Inhibitors. Journal of Biomolecular Screening, 2012, 17, 618-628.	2.6	36
147	416: Amniotic fluid derived mesenchymal stem cells as delivery vehicles for therapeutic factors. American Journal of Obstetrics and Gynecology, 2012, 206, S193.	1.3	Ο
148	Discovery of small molecule HIV-1 integrase dimerization inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3109-3114.	2.2	28
149	Development of a series of 3-hydroxyquinolin-2(1H)-ones as selective inhibitors of HIV-1 reverse transcriptase associated RNase H activity. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3988-3992.	2.2	37
150	A Symmetric Region of the HIV-1 Integrase Dimerization Interface Is Essential for Viral Replication. PLoS ONE, 2012, 7, e45177.	2.5	10
151	Bioluminescence imaging of therapy response does not correlate with FDG-PET response in a mouse model of Burkitt lymphoma. American Journal of Nuclear Medicine and Molecular Imaging, 2012, 2, 353-61.	1.0	6
152	Interplay between HIV Entry and Transportin-SR2 Dependency. Retrovirology, 2011, 8, 7.	2.0	51
153	In Vitro DNA Tethering of HIV-1 Integrase by the Transcriptional Coactivator LEDGF/p75. Journal of Molecular Biology, 2011, 410, 811-830.	4.2	29
154	Magnesium Chelating 2-Hydroxyisoquinoline-1,3(2 <i>H</i> ,4 <i>H</i>)-diones, as Inhibitors of HIV-1 Integrase and/or the HIV-1 Reverse Transcriptase Ribonuclease H Domain: Discovery of a Novel Selective Inhibitor of the Ribonuclease H Function. Journal of Medicinal Chemistry, 2011, 54, 1812-1824.	6.4	113
155	Rilpivirine: a step forward in tailored HIV treatment. Lancet, The, 2011, 378, 201-203.	13.7	17
156	4-[1-(4-Fluorobenzyl)-4-hydroxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acid as a prototype to develop dual inhibitors of HIV-1 integration process. Antiviral Research, 2011, 92, 102-107.	4.1	23
157	Unraveling the Role of Peptidyl-Prolyl Isomerases in Neurodegeneration. Molecular Neurobiology, 2011, 44, 13-27.	4.0	37
158	A Versatile and Practical Synthesis toward the Development of Novel HIVâ€1 Integrase Inhibitors. ChemMedChem, 2011, 6, 343-352.	3.2	15
159	Toward the Discovery of Novel Antiâ€HIV Drugs. Secondâ€Generation Inhibitors of the Cellular ATPase DDX3 with Improved Antiâ€HIV Activity: Synthesis, Structure–Activity Relationship Analysis, Cytotoxicity Studies, and Target Validation. ChemMedChem, 2011, 6, 1371-1389.	3.2	95
160	Synthesis, in vitro and in vivo evaluation of fluorine-18 labelled FE-GW405833 as a PET tracer for type 2 cannabinoid receptor imaging. Bioorganic and Medicinal Chemistry, 2011, 19, 4499-4505.	3.0	52
161	2-Hydroxyisoquinoline-1,3(2H,4H)-diones as inhibitors of HIV-1 integrase and reverse transcriptase RNase H domain: Influence of the alkylation of position 4. European Journal of Medicinal Chemistry, 2011, 46, 535-546.	5.5	60
162	HIV-1 integrase strand-transfer inhibitors: Design, synthesis and molecular modeling investigation. European Journal of Medicinal Chemistry, 2011, 46, 756-764.	5.5	35

#	Article	IF	CITATIONS
163	A PET Brain Reporter Gene System Based on Type 2 Cannabinoid Receptors. Journal of Nuclear Medicine, 2011, 52, 1102-1109.	5.0	44
164	miR669a and miR669q prevent skeletal muscle differentiation in postnatal cardiac progenitors. Journal of Cell Biology, 2011, 193, 1197-1212.	5.2	77
165	The transcriptional co-activator LEDGF/p75 displays a dynamic scan-and-lock mechanism for chromatin tethering. Nucleic Acids Research, 2011, 39, 1310-1325.	14.5	56
166	Depletion of PINK1 affects mitochondrial metabolism, calcium homeostasis and energy maintenance. Journal of Cell Science, 2011, 124, 1115-1125.	2.0	167
167	Association of polymorphisms in the LEDGF/p75 gene (PSIP1) with susceptibility to HIV-1 infection and disease progression. Aids, 2011, 25, 1711-1719.	2.2	22
168	Comparative Analysis of Different Peptidyl-Prolyl Isomerases Reveals FK506-binding Protein 12 as the Most Potent Enhancer of α-Synuclein Aggregation. Journal of Biological Chemistry, 2011, 286, 26687-26701.	3.4	36
169	Role of the PWWP Domain of Lens Epithelium-derived Growth Factor (LEDGF)/p75 Cofactor in Lentiviral Integration Targeting. Journal of Biological Chemistry, 2011, 286, 41812-41826.	3.4	39
170	Morphologic and functional changes in the unilateral 6-hydroxydopamine lesion rat model for Parkinson's disease discerned withÂl¼SPECT and quantitative MRI. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2010, 23, 65-75.	2.0	10
171	New 2-arylnaphthalenediols and triol inhibitors of HIV-1 integrase—Discovery of a new polyhydroxylated antiviral agent. Bioorganic and Medicinal Chemistry, 2010, 18, 5194-5201.	3.0	13
172	New chloro,fluorobenzylindole derivatives as integrase strand-transfer inhibitors (INSTIs) and their mode of action. Bioorganic and Medicinal Chemistry, 2010, 18, 5510-5518.	3.0	15
173	Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor. Bioorganic and Medicinal Chemistry, 2010, 18, 7515-7521.	3.0	59
174	Immunohistochemical detection of transgene expression in the brain using small epitope tags. BMC Biotechnology, 2010, 10, 16.	3.3	35
175	Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nature Chemical Biology, 2010, 6, 442-448.	8.0	428
176	Inhibition of FK506 Binding Proteins Reduces α-Synuclein Aggregation and Parkinson's Disease-Like Pathology. Journal of Neuroscience, 2010, 30, 2454-2463.	3.6	96
177	High-resolution profiling of the LEDGF/p75 chromatin interaction in the ENCODE region. Nucleic Acids Research, 2010, 38, 6135-6147.	14.5	65
178	LEDGF Hybrids Efficiently Retarget Lentiviral Integration Into Heterochromatin. Molecular Therapy, 2010, 18, 552-560.	8.2	144
179	Efficient Gene Transfer Into the Mouse Lung by Fetal Intratracheal Injection of rAAV2/6.2. Molecular Therapy, 2010, 18, 2130-2138.	8.2	33
180	Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors at Scale. Human Gene Therapy, 2010, 21, 1259-1271.	2.7	283

#	Article	IF	CITATIONS
181	Differential Effects of Progenitor Cell Populations on Left Ventricular Remodeling and Myocardial Neovascularization After Myocardial Infarction. Journal of the American College of Cardiology, 2010, 55, 2232-2243.	2.8	104
182	Fetal surgery is a clinical reality. Seminars in Fetal and Neonatal Medicine, 2010, 15, 58-67.	2.3	57
183	Lentiviral Integration and the Role of the Cellular Cofactors LEDGF/p75 of the Cellular Cofactors LEDGF/p75 and Transportin-SR2. , 2010, , 375-406.		Ο
184	Lens Epithelium-derived Growth Factor/p75 Interacts with the Transposase-derived DDE Domain of PogZ. Journal of Biological Chemistry, 2009, 284, 11467-11477.	3.4	82
185	In search of second-generation HIV integrase inhibitors: targeting integration beyond strand transfer. Future Medicinal Chemistry, 2009, 1, 1259-1274.	2.3	11
186	Microwave-Assisted Silver(I)-Mediated Selective O-Alkylation of Aromatic Imidate Systems. Synthesis, 2009, 2009, 2725-2728.	2.3	4
187	721: Combined non-invasive bioluminiscence and magnetic resonance imaging improves detection after pulmonary gene transfer in a fetal mouse model. American Journal of Obstetrics and Gynecology, 2009, 201, S261.	1.3	0
188	722: Fetal tracheal injection technique to target the fetal mouse lung. American Journal of Obstetrics and Gynecology, 2009, 201, S261.	1.3	0
189	Pharmacophoreâ€Based Discovery of Smallâ€Molecule Inhibitors of Protein–Protein Interactions between HIVâ€I Integrase and Cellular Cofactor LEDGF/p75. ChemMedChem, 2009, 4, 1311-1316.	3.2	98
190	Microwaveâ€Assisted Palladium atalyzed Heterogeneous Vinylation of 2(1 <i>H</i>)â€Pyridones. European Journal of Organic Chemistry, 2009, 2009, 4589-4592.	2.4	12
191	Synthesis and biological evaluation of 11C-labeled β-galactosyl triazoles as potential PET tracers for in vivo LacZ reporter gene imaging. Bioorganic and Medicinal Chemistry, 2009, 17, 5117-5125.	3.0	12
192	Exploration of novel thiobarbituric acid-, rhodanine- and thiohydantoin-based HIV-1 integrase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3615-3618.	2.2	61
193	Highly Efficient Multicistronic Lentiviral Vectors with Peptide 2A Sequences. Human Gene Therapy, 2009, 20, 845-860.	2.7	128
194	Docking Studies on a New Human Immodeficiency Virus Integraseâ^'Mgâ^'DNA Complex: Phenyl Ring Exploration and Synthesis of 1H-Benzylindole Derivatives through Fluorine Substitutions. Journal of Medicinal Chemistry, 2009, 52, 569-573.	6.4	40
195	In search of small molecules blocking interactions between HIV proteins and intracellularcofactors. Molecular BioSystems, 2009, 5, 21-31.	2.9	35
196	State-of-the-Art Lentiviral Vectors for Research Use: Risk Assessment and Biosafety Recommendations. Current Gene Therapy, 2009, 9, 459-474.	2.0	109
197	Seeing Genes at Work in the Living Brain with Non-Invasive Molecular Imaging. Current Gene Therapy, 2009, 9, 212-238.	2.0	15
198	LEDGF/p75 and transportin-SR2 are cellular cofactors of HIV integrase and novel targets for antiviral therapy. HIV Therapy, 2009, 3, 171-188.	0.6	4

#	Article	IF	CITATIONS
199	Structural Modification of Diketo Acid Portion in 1H-Benzylindole Derivatives HIV-1 Integrase Inhibitors. Heterocycles, 2009, 78, 947.	0.7	7
200	Diffusion of Myelin Oligodendrocyte Glycoprotein in Living OLN-93 Cells Investigated by Raster-Scanning Image Correlation Spectroscopy (RICS). Journal of Fluorescence, 2008, 18, 813-819.	2.5	17
201	The total synthesis of fukiic acid, an HIV-1 integrase inhibitor. European Journal of Medicinal Chemistry, 2008, 43, 2268-2271.	5.5	10
202	A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H-benzylindole series. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2891-2895.	2.2	38
203	Efficient purification and metabolite analysis of radiotracers using high-performance liquid chromatography and on-line solid-phase extraction. Journal of Chromatography A, 2008, 1189, 323-331.	3.7	22
204	Synthesis and antiviral properties of some polyphenols related to Salvia genus. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4736-4740.	2.2	25
205	Reaction of Rosmarinic Acid with Nitrite Ions in Acidic Conditions: Discovery of Nitro- and Dinitrorosmarinic Acids as New Anti-HIV-1 Agents. Journal of Medicinal Chemistry, 2008, 51, 2575-2579.	6.4	66
206	Noninvasive and Quantitative Monitoring of Adult Neuronal Stem Cell Migration in Mouse Brain Using Bioluminescence Imaging. Stem Cells, 2008, 26, 2382-2390.	3.2	58
207	241: Effects of tracheal occlusion and albumin on proliferation in fetal rats with nitrofen induced congenital diaphragmatic hernia $\hat{a} \in $ A placebo controlled molecular study. American Journal of Obstetrics and Gynecology, 2008, 199, S79.	1.3	0
208	439: Intra-amniotic VEGF administration in fetal rats with nitrofen induced lung hypoplasia – A placebo controlled study. American Journal of Obstetrics and Gynecology, 2008, 199, S131.	1.3	0
209	653: Evaluation of different screening models for optimal pulmonary transduction with lentiviral vectors. American Journal of Obstetrics and Gynecology, 2008, 199, S187.	1.3	Ο
210	FK506 binding protein 12 differentially accelerates fibril formation of wild type alpha-synuclein and its clinical mutants A30P or A53T. Journal of Neurochemistry, 2008, 106, 121-133.	3.9	29
211	Four-tiered π interaction at the dimeric interface of HIV-1 integrase critical for DNA integration and viral infectivity. Virology, 2008, 377, 355-363.	2.4	22
212	Inhibitory profile of a LEDGF/p75 peptide against HIVâ€1 integrase: Insight into integrase–DNA complex formation and catalysis. FEBS Letters, 2008, 582, 1425-1430.	2.8	50
213	Transportin-SR2 Imports HIV into the Nucleus. Current Biology, 2008, 18, 1192-1202.	3.9	231
214	Design, Synthesis, and Biological Evaluation of a Series of 2-Hydroxyisoquinoline-1,3(2 <i>H</i> ,4 <i>H</i>)-diones as Dual Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and the Reverse Transcriptase RNase H Domain. Journal of Medicinal Chemistry, 2008, 51, 7717-7730.	6.4	115
215	Quinolone 3-Carboxylic Acid Pharmacophore: Design of Second Generation HIV-1 Integrase Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 1136-1144.	6.4	82
216	Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 1. Synthesis and Structureâ´`Activity Relationship of a Class of Human Immunodeficiency Virus type 1 Integrase Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 5125-5129.	6.4	151

#	Article	IF	CITATIONS
217	Synthesis and Evaluation of ¹⁸ F- and ¹¹ C-Labeled Phenyl-Galactopyranosides as Potential Probes for <i>in Vivo</i> Visualization of LacZ Gene Expression using Positron Emission Tomography. Bioconjugate Chemistry, 2008, 19, 441-449.	3.6	43
218	Alternative Splicing and Caspase-Mediated Cleavage Generate Antagonistic Variants of the Stress Oncoprotein LEDGF/p75. Molecular Cancer Research, 2008, 6, 1293-1307.	3.4	34
219	Mutations in Human Immunodeficiency Virus Type 1 Integrase Confer Resistance to the Naphthyridine L-870,810 and Cross-Resistance to the Clinical Trial Drug GS-9137. Antimicrobial Agents and Chemotherapy, 2008, 52, 2069-2078.	3.2	49
220	Preclinical Evaluation of 1H-Benzylindole Derivatives as Novel Human Immunodeficiency Virus Integrase Strand Transfer Inhibitors. Antimicrobial Agents and Chemotherapy, 2008, 52, 2861-2869.	3.2	17
221	Virus Evolution Reveals an Exclusive Role for LEDGF/p75 in Chromosomal Tethering of HIV. PLoS Pathogens, 2007, 3, e47.	4.7	104
222	Non-invasive imaging of neuropathology in a rat model of α-synuclein overexpression. Neurobiology of Aging, 2007, 28, 248-257.	3.1	45
223	Identification of the LEDGF/p75 Binding Site in HIV-1 Integrase. Journal of Molecular Biology, 2007, 365, 1480-1492.	4.2	123
224	Differential Interaction of HIV-1 Integrase and JPO2 with the C Terminus of LEDGF/p75. Journal of Molecular Biology, 2007, 372, 407-421.	4.2	75
225	Synthesis and Preliminary Evaluation of18F- or11C-Labeled Bicyclic Nucleoside Analogues as Potential Probes for Imaging Varicella-Zoster Virus Thymidine Kinase Gene Expression Using Positron Emission Tomography. Journal of Medicinal Chemistry, 2007, 50, 1041-1049.	6.4	14
226	A p-[18F]Fluoroethoxyphenyl Bicyclic Nucleoside Analogue as a Potential Positron Emission Tomography Imaging Agent for Varicella-Zoster Virus Thymidine Kinase Gene Expression. Journal of Medicinal Chemistry, 2007, 50, 6627-6637.	6.4	10
227	Novel Virtual Screening Protocol Based on the Combined Use of Molecular Modeling and Electron-Ion Interaction Potential Techniques To Design HIV-1 Integrase Inhibitors. Journal of Chemical Information and Modeling, 2007, 47, 1536-1544.	5.4	32
228	Comparative Analysis of Adeno-Associated Viral Vector Serotypes 1, 2, 5, 7, And 8 in Mouse Brain. Human Gene Therapy, 2007, 18, 195-206.	2.7	273
229	Lentiviral nuclear import: a complex interplay between virus and host. BioEssays, 2007, 29, 441-451.	2.5	42
230	New 4-[(1-Benzyl-1H-indol-3-yl)carbonyl]-3-hydroxyfuran-2(5H)-ones, β-Diketo Acid Analogs as HIV-1 Integrase Inhibitors. Archiv Der Pharmazie, 2007, 340, 292-298.	4.1	27
231	Toward novel HIV-1 integrase binding inhibitors: Molecular modeling, synthesis, and biological studies. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5370-5373.	2.2	27
232	Discovery of novel non-cytotoxic salicylhydrazide containing HIV-1 integrase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6472-6475.	2.2	41
233	Synthesis and biological evaluation of an 1231-labeled bicyclic nucleoside analogue (BCNA) as potential SPECT tracer for VZV-tk reporter gene imaging. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3458-3462.	2.2	6
234	Concise Review: Therapeutic Strategies for Parkinson Disease Based on the Modulation of Adult Neurogenesis. Stem Cells, 2007, 25, 263-270.	3.2	79

#	Article	IF	CITATIONS
235	Fetal gene transfer with lentiviral vectors: long-term in vivo follow-up evaluation in a rat model. American Journal of Obstetrics and Gynecology, 2007, 196, 352.e1-352.e6.	1.3	16
236	584: Ex-vivo assessment of the effect of airway epithelial barrier disruption on transduction efficiency of a lentiviral vector in fetal rat tracheas. American Journal of Obstetrics and Gynecology, 2007, 197, S168.	1.3	0
237	Local origin and activity-dependent generation of nestin-expressing protoplasmic astrocytes in CA1. Brain Structure and Function, 2007, 212, 19-35.	2.3	28
238	Simple criterion for selection of flavonoid compounds with anti-HIV activity. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1226-1232.	2.2	35
239	Lentiviral Vectors Mediate Efficient and Stable Gene Transfer in Adult Neural Stem Cells <i>In Vivo</i> . Human Gene Therapy, 2006, 17, 635-650.	2.7	76
240	RNAi-based treatment of HIV/AIDS: Current status and perspectives. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 227-235.	0.5	4
241	The central DNA flap of the human immunodeficiency virus type 1 is important for viral replication. Biochemical and Biophysical Research Communications, 2006, 349, 1100-1110.	2.1	25
242	Comparison of lentiviral vector titration methods. BMC Biotechnology, 2006, 6, 34.	3.3	130
243	Long term pulmonary gene therapy with a lentiviral vector in aÂfetalÂrat model. American Journal of Obstetrics and Gynecology, 2006, 195, S22.	1.3	4
244	Transduction of human pulmonary epithelial cell lines with a lentiviral vector. American Journal of Obstetrics and Gynecology, 2006, 195, S179.	1.3	0
245	Cellular co-factors of HIV-1 integration. Trends in Biochemical Sciences, 2006, 31, 98-105.	7.5	180
246	Microwave-Assisted Synthesis of Fluoroquinolones and Their Nucleosides as Inhibitors of HIV Integrase. Collection of Czechoslovak Chemical Communications, 2006, 71, 978-990.	1.0	9
247	Overexpression of the Lens Epithelium-Derived Growth Factor/p75 Integrase Binding Domain Inhibits Human Immunodeficiency Virus Replication. Journal of Virology, 2006, 80, 11498-11509.	3.4	154
248	Transient and Stable Knockdown of the Integrase Cofactor LEDGF/p75 Reveals Its Role in the Replication Cycle of Human Immunodeficiency Virus. Journal of Virology, 2006, 80, 1886-1896.	3.4	198
249	The aggregation of alphaâ€synuclein is stimulated by FK506 binding proteins as shown by fluorescence correlation spectroscopy. FASEB Journal, 2006, 20, 524-526.	0.5	62
250	Noninvasive Monitoring of Long-Term Lentiviral Vector-Mediated Gene Expression in Rodent Brain with Bioluminescence Imaging. Molecular Therapy, 2006, 14, 423-431.	8.2	60
251	Parkin Protects against Neurotoxicity in the 6-Hydroxydopamine Rat Model for Parkinson's Disease. Molecular Therapy, 2006, 14, 716-723.	8.2	109
252	The aggregation of alphaâ€synuclein is stimulated by FK506 Binding Proteins as shown by Fluorescence Correlation Spectroscopy. FASEB Journal, 2006, 20, .	0.5	0

#	ARTICLE	IF	CITATIONS
253	Lentiviral Vectors Mediate Efficient and Stable Gene Transfer in Adult Neural Stem Cells In Vivo. Human Gene Therapy, 2006, .	2.7	0
254	Upscaling of lentiviral vector production by tangential flow filtration. Journal of Gene Medicine, 2005, 7, 1299-1310.	2.8	143
255	Synthesis of New Potential HIV-1 Integrase Inhibitors ChemInform, 2005, 36, no.	0.0	0
256	Integrase Mutants Defective for Interaction with LEDGF/p75 Are Impairedin Chromosome Tethering and HIV-1Replication*. Journal of Biological Chemistry, 2005, 280, 25517-25523.	3.4	212
257	Measuring proteinâ€protein interactions inside living cells using single color fluorescence correlation spectroscopy. Application to human immunodeficiency virus type 1 integrase and LEDGF/p75. FASEB Journal, 2005, 19, 1039-1041.	0.5	40
258	The Interaction of LEDGF/p75 with Integrase Is Lentivirus-specific and Promotes DNA Binding. Journal of Biological Chemistry, 2005, 280, 17841-17847.	3.4	182
259	Pharmacophore-Based Design of HIV-1 Integrase Strand-Transfer Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 7084-7088.	6.4	160
260	Evaluation of the activity of HIV-1 integrase over-expressed in eukaryotic cells. Biochemical and Biophysical Research Communications, 2005, 327, 261-267.	2.1	4
261	Positional effects of the central DNA flap in HIV-1-derived lentiviral vectors. Biochemical and Biophysical Research Communications, 2005, 328, 987-994.	2.1	16
262	HIV-1 integration: an interplay between HIV-1 integrase, cellular and viral proteins. AIDS Reviews, 2005, 7, 26-43.	1.0	61
263	Identification and Characterization of a Functional Nuclear Localization Signal in the HIV-1 Integrase Interactor LEDGF/p75. Journal of Biological Chemistry, 2004, 279, 33421-33429.	3.4	86
264	Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. Aids, 2004, 18, 2019-2028.	2.2	71
265	Expression of HIV-1 integrase in CEM cells inhibits HIV-1 replication. Journal of Gene Medicine, 2004, 6, 268-277.	2.8	1
266	Efficient 3D Database Screening for Novel HIV-1 IN Inhibitors. Journal of Chemical Information and Computer Sciences, 2004, 44, 1450-1455.	2.8	44
267	Synthesis of New Potential HIV-1 Integrase Inhibitors. Heterocycles, 2004, 63, 2727.	0.7	19
268	N-Aminoimidazole Derivatives Inhibiting Retroviral Replication via a Yet Unidentified Mode of Action. Journal of Medicinal Chemistry, 2003, 46, 1546-1553.	6.4	40
269	Establishment of an in vitro assay system mimicking human immunodeficiency virus type 1-induced neural cell death and evaluation of inhibitors thereof. Journal of Virological Methods, 2003, 108, 195-203.	2.1	4
270	Lentiviral Vector-Mediated Delivery of Short Hairpin RNA Results in Persistent Knockdown of Gene Expression in Mouse Brain. Human Gene Therapy, 2003, 14, 1799-1807.	2.7	114

#	Article	IF	CITATIONS
271	HIV-1 Integrase Forms Stable Tetramers and Associates with LEDGF/p75 Protein in Human Cells. Journal of Biological Chemistry, 2003, 278, 372-381.	3.4	608
272	Development of Resistance against Diketo Derivatives of Human Immunodeficiency Virus Type 1 by Progressive Accumulation of Integrase Mutations. Journal of Virology, 2003, 77, 11459-11470.	3.4	94
273	Impact of the Central Polypurine Tract on the Kinetics of Human Immunodeficiency Virus Type 1 Vector Transduction. Journal of Virology, 2003, 77, 4685-4694.	3.4	120
274	LEDGF/p75 Is Essential for Nuclear and Chromosomal Targeting of HIV-1 Integrase in Human Cells. Journal of Biological Chemistry, 2003, 278, 33528-33539.	3.4	432
275	Neuropathology and Neurodegeneration in Rodent Brain Induced by Lentiviral Vectormediated Overexpression of α‧ynuclein. Brain Pathology, 2003, 13, 364-372.	4.1	103
276	A Short Course on Virology / Vectorology / Gene Therapy. Current Gene Therapy, 2003, 3, 495-499.	2.0	12
277	Biosafety of Lentiviral Vectors. Current Gene Therapy, 2003, 3, 517-525.	2.0	24
278	Inhibition of Human Immunodeficiency Virus Type 1 Integration by Diketo Derivatives. Antimicrobial Agents and Chemotherapy, 2002, 46, 3292-3297.	3.2	52
279	In Search of Authentic Inhibitors of HIV-1 Integration. Antiviral Chemistry and Chemotherapy, 2002, 13, 1-15.	0.6	29
280	DNA-induced Polymerization of HIV-1 Integrase Analyzed with Fluorescence Fluctuation Spectroscopy. Journal of Biological Chemistry, 2002, 277, 38045-38052.	3.4	35
281	Characterization of Lentiviral Vector-Mediated Gene Transfer in Adult Mouse Brain. Human Gene Therapy, 2002, 13, 841-853.	2.7	127
282	New Class of HIV Integrase Inhibitors that Block Viral Replication in Cell Culture. Current Biology, 2002, 12, 1169-1177.	3.9	100
283	Assays for the Evaluation of HIV-1 Integrase Inhibitors. , 2001, 160, 139-155.		35
284	Highâ€level expression of active HIVâ€1 integrase from a synthetic gene in human cells. FASEB Journal, 2000, 14, 1389-1399.	0.5	46
285	Viral Entry as the Primary Target for the Anti-HIV Activity of Chicoric Acid and Its Tetra-Acetyl Esters. Molecular Pharmacology, 2000, 58, 641-648.	2.3	109
286	DNA-Dependent Protein Kinase Is Not Required for Efficient Lentivirus Integration. Journal of Virology, 2000, 74, 11278-11285.	3.4	84
287	Polyanionic (i.e., Polysulfonate) Dendrimers Can Inhibit the Replication of Human Immunodeficiency Virus by Interfering with Both Virus Adsorption and Later Steps (Reverse Transcriptase/Integrase) in the Virus Replicative Cycle. Molecular Pharmacology, 2000, 58, 1100-1108.	2.3	149
288	Activity of recombinant HIV-1 integrase on mini-HIV DNA. Nucleic Acids Research, 1999, 27, 2202-2210.	14.5	47

#	Article	IF	CITATIONS
289	Full-Length Genomic Sequence of an HIV Type 1 Subtype G from Kinshasa. AIDS Research and Human Retroviruses, 1999, 15, 585-589.	1.1	7
290	Nuclear Localization of Human Immunodeficiency Virus Type 1 Integrase Expressed as a Fusion Protein with Green Fluorescent Protein. Virology, 1999, 258, 327-332.	2.4	74
291	Chicoric Acid Analogues as HIV-1 Integrase Inhibitors. Journal of Medicinal Chemistry, 1999, 42, 1401-1414.	6.4	149
292	Failure to Quantify Viral Load with Two of the Three Commercial Methods in a Pregnant Woman Harboring an HIV Type 1 Subtype G Strain. AIDS Research and Human Retroviruses, 1998, 14, 453-459.	1.1	67
293	Formation of a DNA Loop at the Replication Fork Generated by Bacteriophage T7 Replication Proteins. Journal of Biological Chemistry, 1998, 273, 5260-5270.	3.4	56
294	Human Immunodeficiency Virus Glycoprotein gp120 as the Primary Target for the Antiviral Action of AR177 (Zintevir). Molecular Pharmacology, 1998, 53, 340-345.	2.3	118
295	Mode of Interaction of G-Quartets with the Integrase of Human Immunodeficiency Virus Type 1. Molecular Pharmacology, 1997, 52, 771-780.	2.3	82
296	A two plasmid co-expression system in Escherichia coli for the production of virion-like reverse transcriptase of the human immunodeficiency virus type 1. Journal of Virological Methods, 1996, 61, 113-125.	2.1	21
297	Chemical crosslinking of the subunits of HIVâ€1 reverse transcriptase. Protein Science, 1996, 5, 278-286.	7.6	13
298	[35] DNA substrates for studying replication mechanisms: Synthetic replication forks. Methods in Enzymology, 1995, 262, 457-466.	1.0	2
299	Inhibition of visna virus replication and cytopathic effect in sheep choroid plexus cell cultures by selected anti-HIV agents. Antiviral Research, 1995, 27, 49-57.	4.1	16
300	Characterization of HIV-1 Strains Isolated from Patients Treated with TIBO R82913. AIDS Research and Human Retroviruses, 1994, 10, 39-46.	1.1	49
301	Coordination of leading and lagging strand DNA synthesis at the replication fork of bacteriophage T7. Cell, 1994, 77, 157-166.	28.9	92
302	Specific HIV-1 Reverse Transcriptase Inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 1992, 6, 47-53.	0.5	12
303	Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis. Virology, 1992, 188, 900-904.	2.4	55
304	Integrase as a Novel Target for the Inhibition of Human Immunodeficiency Virus Type 1 Infection: Current Status and Future Perspectives. , 0, , 71-96.		1